WO2003033696A1 - Compose antisens vegf - Google Patents
Compose antisens vegf Download PDFInfo
- Publication number
- WO2003033696A1 WO2003033696A1 PCT/JP2002/010796 JP0210796W WO03033696A1 WO 2003033696 A1 WO2003033696 A1 WO 2003033696A1 JP 0210796 W JP0210796 W JP 0210796W WO 03033696 A1 WO03033696 A1 WO 03033696A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antisense compound
- vegf antisense
- different
- same
- vegf
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
L'invention concerne un composé représenté par la formule générale HO-B1-B2-B3-B4-B5-B6-B7-B8-B9-B10-B11-B12-B13-B14B15-B16-B17-B18-B19-B20-B21-B22-H (dans laquelle B1 à B3, B8, B11 et B20 peuvent être identiques ou différents et représentent chacun Cp etc. ; B4, B5, B7, B9, B12, B14 à B16 et B21 peuvent être identiques ou différents et représentent chacun Ap etc. ; B6, B10, B13 et B17 peuvent être identique ou différents et représentent chacun Gp etc. ; B18 et B19 peuvent être identiques ou différents et représentent chacun Tp etc. ; et B22 représente Tt etc. ), ainsi qu'un sel pharmacologiquement acceptable de ce composé.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001/320096 | 2001-10-18 | ||
JP2001320096 | 2001-10-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003033696A1 true WO2003033696A1 (fr) | 2003-04-24 |
Family
ID=19137535
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2002/010796 WO2003033696A1 (fr) | 2001-10-18 | 2002-10-17 | Compose antisens vegf |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2003033696A1 (fr) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998039352A1 (fr) * | 1997-03-07 | 1998-09-11 | Takeshi Imanishi | Nouveaux analogues de bicyclonucleoside et d'oligonucleotide |
WO1999014226A2 (fr) * | 1997-09-12 | 1999-03-25 | Exiqon A/S | Analogues d'oligonucleotides |
WO2000047599A1 (fr) * | 1999-02-12 | 2000-08-17 | Sankyo Company, Limited | Nouveaux analogues de nucleosides et d'oligonucleotides |
-
2002
- 2002-10-17 WO PCT/JP2002/010796 patent/WO2003033696A1/fr active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998039352A1 (fr) * | 1997-03-07 | 1998-09-11 | Takeshi Imanishi | Nouveaux analogues de bicyclonucleoside et d'oligonucleotide |
WO1999014226A2 (fr) * | 1997-09-12 | 1999-03-25 | Exiqon A/S | Analogues d'oligonucleotides |
WO2000047599A1 (fr) * | 1999-02-12 | 2000-08-17 | Sankyo Company, Limited | Nouveaux analogues de nucleosides et d'oligonucleotides |
Non-Patent Citations (4)
Title |
---|
CHRISTENSEN U. ET AL.: "Stopped-flow kinetics of locked nucleic acid(LNA)-oligonucleotide duplex formation: studies of LNA-DNA and DNA-DNA interactions", BIOCHEM. J., vol. 354, no. 3, 15 March 2001 (2001-03-15), pages 481 - 484, XP002971047 * |
KUMAR R. ET AL.: "The first analogues of LNA(locked nucleic acids): phosphorothioate-LNA and 2'-THIO-LNA", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 8, no. 16, 1998, pages 2219 - 2222, XP002094302 * |
NOMURA M. ET AL.: "Possible participation of autocrine and paracrine vascular endotherial growth factors in hypoxia-induced proliferation of endotherial cells and pericytes", J. BIOL. CHEM., vol. 270, no. 47, 1995, pages 28316 - 28324, XP002915173 * |
SATOSHI OBIKA: "Tobu rittai haiza o kotei shita jinko nucleoside oyobi oligonucleotide-rui no gosei to sono tokusei", JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, vol. 120, no. 2, 2000, pages 147 - 158, XP002971048 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005009539A3 (fr) | Composes pour l'inflammation et utilisations liees au systeme immunitaire | |
WO2009014100A1 (fr) | INDUCTEUR DE PROTÉINE p27 | |
WO2006034402A3 (fr) | Composes pour l'inflammation et applications associees aux troubles immuns | |
HK1071510A1 (en) | Acetylene derivatives having mglur 5 antagonistic activity | |
CA2497074A1 (fr) | Ketoenoles spirocycliques substitues | |
WO2006007384A3 (fr) | Antibiotiques contenant des complexes de l'acide borinique, et leur procede d'utilisation | |
TW200642689A (en) | Immunosuppressive agent and anti-tumor agent comprising heterocyclic compound as active ingredient | |
WO2007117465A3 (fr) | Composés d'indazole | |
WO2001014376A8 (fr) | Nouveaux composes spiro | |
WO2002062775A1 (fr) | Dérivé de 2-acylaminothiazole ou son sel | |
WO2004012759A3 (fr) | Utilisation de l'erythropoietine | |
HK1090647A1 (en) | Oxazolidinone-quinolone hybrid antibiotics | |
DE602004006994D1 (en) | 3-aryloxy und 3-heteroaryloxy substituierte benzo(b) thiophene als therapeutische wirkstoffe mit pi3k aktivität | |
WO2003032962A3 (fr) | Antibiotiques a double action | |
WO2007112014A3 (fr) | Nouvelles combinaisons thérapeutiques pour le traitement de la dépression | |
MX2007000240A (es) | Derivados de [1.2]-oxazin-3,5-diona y dihidropirona sustituidos con fenilo. | |
PE20030061A1 (es) | 1-biaril-1,8-naftiridin-4-ona como inhibidores de fosfodiesterasa-4 | |
WO2006083841A3 (fr) | Esters therapeutiques | |
PL359763A1 (en) | Fungicidal combinations of active agents | |
MY162231A (en) | Prophylactic device carrying a microbiocidal composition | |
WO2002017854A3 (fr) | Antibiotiques cephalosporine et leurs promedicaments | |
WO2004043928A3 (fr) | N-sulfonyl-4-methylene-amino-3-hydroxy-2-pyridones | |
WO2003033696A1 (fr) | Compose antisens vegf | |
IL196418A0 (en) | Thieno[3,2-c]pyridine-7-carboxylic acid derivatives | |
WO2005021559A3 (fr) | Oxazaborolidines constituant des effecteurs bacteriens |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |